Stock Monitor: MYOS RENS Technology Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free earnings report on Lipocine Inc. (NASDAQ: LPCN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LPCN. The Company reported its full fiscal year 2017 operating and financial results on March 12, 2018. The specialty pharmaceutical Company missed earnings estimates. Register today and get access to over 1000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for MYOS RENS Technology Inc. (NASDAQ: MYOS), which also belongs to the Healthcare sector as the Company Lipocine. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Lipocine most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Earnings Highlights and Summary
For the full fiscal year ended December 31, 2017, and before that, Lipocine had not generated any revenues from product sales, and does not expect to do so until one of the Company's product candidates receives approval from the US Food and Drug Administration (FDA). Lipocine's revenues to date have been generated substantially from license fees, milestone payments, and research support from its licensees. Since its inception through December 31, 2017, the Company has generated $27.5 million in revenues under its various license and collaboration arrangements and from government grants.
During FY17, Lipocine's research and development (R&D) expenses were $11.0 million compared to $8.1 million during FY16. The increase in the Company's R&D expenses was primarily due to increased contract research organization and consultant costs TLANDO, related to the Dosing Validation (DV) and Dosing Flexibility (DF) clinical studies; increased contract manufacturing costs for LPCN 1107; and increased outside services expenses related to the Advisory Committee meeting for TLANDO. These increases were offset by decreased contract research organization costs for LPCN 1111; a decrease in validation and commercial batch manufacturing costs for TLANDO; and a decrease in contract research organization costs for LPCN 1107.
For FY17, Lipocine's general and administrative (G&A) expenses were $10.2 million compared to $10.4 million during FY16. The decrease in the Company's G&A expenses was primarily due to decreases in pre-commercialization marketing and sales activities related to TLANDO, offset by an increase related to a class-action litigation settlement liability.
For FY17, Lipocine recorded an operating loss of $21.2 million compared to $19.2 million in FY16.
Lipocine reported a net loss of $21.0 million, or $1.05 loss per diluted share, in FY17 compared to a net loss of $19.0 million, or $1.04 loss per diluted share, in FY16. The Company's reported loss was higher than analysts' estimates for a loss of $1.03 per share.
Research and Development
Lipocine currently has three products in the development pipeline - TLANDO, LPCN 1111, and LPCN 1107 - and the Company continues to conceptualize and discuss new indications for current products and new development opportunities.
As of December 31, 2017, Lipocine had cash, cash equivalents, and marketable securities of $21.5 million compared to $26.8 million as of December 31, 2016.
In January 2018, the Company received $10 million through a Loan and Security Agreement with Silicon Valley Bank.
Stock Performance Snapshot
April 19, 2018 - At Thursday's closing bell, Lipocine's stock declined 4.14%, ending the trading session at $1.62.
Volume traded for the day: 131.96 thousand shares.
Stock performance in the last month – up 8.72%; and previous three-month period – up 13.29%
After yesterday's close, Lipocine's market cap was at $33.53 million.
The stock is part of the Healthcare sector, categorized under the Drugs - Generic industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.